多西他赛联合口服氟尿嘧啶改善III期胃癌患者疗效:JACCRO GC-07随机对照试验中期分析
JACCRO GC-07研究为随机III期试验,比较术后S-1联合多西他赛与单用S-1在R0切除的III期胃癌患者中的疗效。第二次中期分析(915例入组,中位随访12.5个月)显示,联合组3年无复发生存率66%优于单药组50%,风险比0.632,试验因独立数据安全监查委员会建议提前终止。
要点
- S-1联合多西他赛组3年无复发生存率66%,单用S-1组为50%。
- 联合组3级及以上不良事件(尤其中性粒细胞减少和白细胞减少)发生率更高,但均可管理。
- 中期分析显示联合方案优效,研究入组提前终止。
核心结论
- 在III期胃癌患者中,S-1联合多西他赛有效且安全性顾虑较少。
- 本研究结果可能也适用于围手术期辅助化疗或放化疗非标准的国家。
研究设计与样本
- 随机III期试验,旨在证明术后S-1联合多西他赛优于单用S-1,用于R0切除的病理III期胃癌患者。
- 计划样本量1100例,以检测3年无复发生存率提高7%为主要终点(风险比0.78;双侧α=0.05;β=0.2)。
主要发现
- 第二次中期分析在915例入组患者中发生216个事件时进行(中位随访12.5个月)。
- S-1联合多西他赛组3年无复发生存率为66%,单用S-1组为50%(风险比0.632;99.99% CI 0.400至0.998;分层log-rank检验P<.001)。
- 独立数据安全监查委员会建议终止入组。
- S-1联合多西他赛组3级及以上不良事件(尤其中性粒细胞减少和白细胞减少)发生率更高,但所有事件均可管理。
临床怎么用
- 作者认为,在III期胃癌患者中,S-1联合多西他赛有效且安全性顾虑较少。
- 作者认为,本研究结果可能也适用于围手术期辅助化疗或放化疗非标准的国家。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: S-1 is a standard postoperative adjuvant chemotherapy for patients with stage II or III gastric cancer in Asia. Neoadjuvant or perioperative strategies dominate in Western countries, and docetaxel has recently shown significant survival benefits when combined with other standard regimens in advanced cancer and perioperative settings. PATIENTS AND METHODS: This randomized phase III study was designed to prove the superiority of postoperative S-1 plus docetaxel over S-1 alone for R0 resection of pathologic stage III gastric cancer. The sample size of 1,100 patients was necessary to detect a 7% increase in 3-year relapse-free survival as the primary end point (hazard ratio, 0.78; 2-sided α = .05; β = .2). RESULTS: The second interim analysis was conducted when the number of events reached 216 among 915 enrolled patients (median follow-up, 12.5 months). Analysis demonstrated the superiority of S-1 plus docetaxel (66%) to S-1 (50%) for 3-year relapse-free survival (hazard ratio, 0.632; 99.99% CI, 0.400 to 0.998; stratified log-rank test, P < .001), and enrollment was terminated as recommended by the independent data and safety monitoring committee. Incidences of grade 3 or greater adverse events, particularly neutropenia and leukopenia, were higher in the S-1 plus docetaxel group, but all events were manageable. CONCLUSION: Addition of docetaxel to S-1 is effective with few safety concerns in patients with stage III gastric cancer. The present findings may also be applicable in countries in which perioperative adjuvant chemotherapy or chemoradiation is not standard.
引用
- Yoshida K, Kodera Y, Kochi M, et al. Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial. J Clin Oncol. 2019. PMID: 30925125. doi:10.1200/JCO.18.01138
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。